MedTrace Logo

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

NCT07427576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2026-02-23

No results posted yet for this study

Summary

House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with rhinoconjunctivitis due to sensitisation to these mites (94.7%).

Immunotherapy is indicated for the treatment of allergic rhinoconjunctivitis and is capable of altering the natural course of allergic diseases.

The aim of the study was to evaluate the efficacy and safety of Clustoid® Max Forte in the treatment of patients with respiratory allergy to Dermatophagoides/Blomia tropicalis.

Conditions

  • Mite Allergy
  • Dermatophagoides Farinae Allergy
  • Dermatophagoides Pteronyssinus Allergy
  • Rhinitis, Allergic
  • Asthma
  • Rhinoconjunctivitis

Interventions

BIOLOGICAL

Clustoid® Max Forte

Clustoid® Max Forte for Dermatophagoides (D. pteronyssinus, D. farinae)/ Blomia tropicalis at concentrations of 30,000/30,000 TU/mL or 30,000/10,000 TU/mL

Sponsors & Collaborators

  • Inmunotek S.L.

    lead INDUSTRY

Principal Investigators

  • Cristina González Colino · Hospital Universitario Nuestra Señora de Candelaria

Eligibility

Min Age
5 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-08-31
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07427576 on ClinicalTrials.gov